Evotec Signs a License Agreement with Kazia Therapeutics for Clinical Development of EVT801
Shots: Evotec to receive a up front as well as research funding for biomarker development and CMC and is eligible to receive $361.21M as clinical & commercial milestones along with royalties on the net sales of EVT801, which will be shared with Sanofi (partner in the discovery and the development of EVT801) Kazia to get […]